Novo Holdings is pleased to announce the appointment of Megan Bailey, CEO of Personal Genome Diagnostics (PGDx), to the Novo Advisory Group (NAG) – an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its larger life science investments.

Kasim Kutay, CEO of Novo Holdings, said: “With a track record at the intersection of personalised medicine, diagnostics, and health care IT, Megan brings a strong understanding to the NAG of some of the most important convergence trends in the world of healthcare. I am delighted to welcome Megan to the NAG and very much look forward to her contributions.”

Megan Bailey has over 19 years of leadership experience in the healthcare industry. Before becoming CEO of PGDx, she served as the company’s Chief Commercial Officer, leading the marketing, sales, and customer support teams. Before that, Megan was Vice President, Marketing. PGDx was founded in 2010 to help bring novel genomic diagnostic approaches to patients with cancer.

Prior to joining PGDx in 2018, Megan had held several senior commercial roles at diagnostics company Ventana Medical Systems and subsequently at Roche.

Megan Bailey said: “It is an honour to join this group of extraordinary industry leaders and a team of people so committed to impacting health, science, and society in a meaningful way, and I look forward to contributing to this noble mission.”

About Megan Bailey

American citizen

Career

2020 – CEO, PDGx

2018 – 2020: Various roles with PDGx, including Chief Commercial
Officer and Vice President, Marketing

2016 – 2018: Senior Director, Sales, Roche

2012 – 2015: Group Marketing Manager, Roche

2008 – 2012: Various positions at Ventana Medical Systems, including Senior International Product Manager

Current board positions
Megan serves on the UMB Foundation Board of Trustees and the Army West Point Athletic Association Board of Directors.

Education
Megan is a graduate of the United States Military Academy at West Point and earned her Master of Public Health from the University of North Carolina – Chapel Hill.

About Novo Holdings A/S

Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets.

Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.